

July 20, 2016  
SBI Pharmaceuticals Co., Ltd.

**Registration of a U. S. Patent for Treatment of Influenza Virus Infection  
through Joint Application with Tokushima University**

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)\*, hereby announces that a patent has recently been registered in the United States of America for the treatment of influenza virus infection.

This patent was filed jointly with Tokushima University (Main campus: Tokushima-city; President: Sumihare Noji).

U. S. Patent number: US 9,351,949 B2  
Title of invention: Prophylactic/Therapeutic Agent for Influenza Virus Infection  
Assignees: SBI Pharmaceuticals Co., Ltd.; Tokushima University  
Filing date: June 3, 2013

The corresponding patent was registered in Japan as of April 22, 2016. (Please refer to our [news release](#) dated May 18, 2016.)

SBI Pharmaceuticals will continue to pursue various potential applications of 5-ALA, and focus on research and development to provide pharmaceuticals that satisfy the unmet medical needs of as many people as possible around the world.

\*: 5-aminolevulinic acid (5-ALA)

An amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in food such as shochu lees, red wine and Asian ginseng. It is also known as a material forming chloroplasts in plants.

\*\*\*\*\*

For further information, please contact:

SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095